Recent 8-K filings for PROF
Highest-materiality recent filing
Profound Medical Reports Strong Q1 2026 Results with 104% Revenue Growth and Humana Coverage
- Revenue grew 104% year-over-year to $5.3M, with $2.5M recurring and $2.9M capital equipment.
- Net loss improved 34% to $7.0M ($0.19 per share) from $10.7M in Q1 2025.
-
CAPTAIN randomized trial: whole-gland TULSA patients 2.1x more likely to preserve erectile function and pad-free continence vs robotic prostatectomy (p=0.004); hospitalizations 0.7% vs 6.3%.
-
Profound Medical, Telix sign co-education deal pairing PSMA-PET imaging with TULSA-PRO therapy
Co-education agreement pairs Telix's PSMA-PET agents Gozellix and Illuccix with Profound's MRI-guided, incisionless TULSA-PRO platform in prostate care.
-
Profound Medical prelim Q3 2026 revenue $9.8-10.0M, up ~85-89% YoY and 45-47% above consensus
Preliminary Q3 2026 total revenue expected at $9.8M-$10.0M, versus Bloomberg mean analyst consensus of $6.78M as of Oct 7, 2026.
-
Profound Medical management to attend Lake Street BIG10 Conference on Sept 10, 2026
Management participates in Lake Street Capital Markets 'BIG10' Conference in New York City on September 10, 2026.
-
Profound Medical appoints Richard Fabian as President; Burtnyk becomes CTO
Richard Fabian, former CEO of FUJIFILM Sonosite, named President effective Sept 1, 2026.
-
Profound Medical launches new TDC software to enable up to 6 TULSA procedures per day
New TDC software deployed across TULSA-PRO installed base; adds real-time iMRI control and UI/hardware improvements.
-
Profound Medical appoints Matthew Sobczyk interim CFO; Dewan resigns with $375K severance
Matthew Sobczyk, CPA, CA, promoted from Corporate Controller to Interim CFO effective Aug 14, 2026; base salary CAD 300,414.58, 15% target bonus.
-
Profound Medical launches 'Let's Huddle' patient community for prostate care
Launched Aug 13, 2026: global patient community 'Let's Huddle' for prostate care education and support.
-
Revenue $2.5M, up 12% YoY; $3.1M of TULSA shipments shifted to Q3 due to logistics, resolved.
-
CAPTAIN trial: TULSA preserves penile length vs 0.65 cm loss with robotic RP at 1 month
No median change in penile length at 1 month for TULSA vs 0.65 cm reduction for robotic RP.
-
Profound Medical to report Q2 2026 results on August 6, 2026, after market close
Q2 2026 financial results to be released after market close on Thursday, August 6, 2026.
-
Profound Medical's TULSA Procedure to be featured at SRS Annual Meeting July 23-26
TULSA Procedure highlighted in multiple presentations at SRS2026 in Fort Lauderdale, FL.
-
Profound Medical 2026 AGM: All director nominees elected; incentive plan approved with 36% against
Arthur Rosenthal re-elected with 79.0% for vs 21.0% withheld; lowest support among eight nominees.
-
Profound Medical to present TULSA Procedure data at AUA2026 and explore PSMA PET integration
Four oral presentations on TULSA Procedure at AUA Annual Meeting in Washington, DC on May 16, 2026.
-
Profound Medical Reports Strong Q1 2026 Results with 104% Revenue Growth and Humana Coverage
Revenue grew 104% year-over-year to $5.3M, with $2.5M recurring and $2.9M capital equipment.
-
Profound Medical to release Q1 2026 results on May 7, conference call to follow
Plans to release Q1 2026 financial results after market close on May 7, 2026.
-
Profound Medical to present at Bloom Burton healthcare conf on Apr 22, 2026
Presentation at 2026 Bloom Burton & Co. Healthcare Investor Conference on Apr 22, 2026, 10:00 a.m. ET.
-
Profound Medical to present TULSA-PRO data at SIR 2026 in Toronto, April 11-15
Five oral presentations on April 12 during 'Men's Health 1' session at SIR Annual Meeting.
-
Texas Prostate hits 100th TULSA Procedure; volumes up 500% under new Medicare model
Texas Prostate, led by Dr. James Cochran, performed its 100th TULSA Procedure at Dallas Medical Center.
-
CAPTAIN trial meets primary safety endpoint: TULSA superior to robotic RP on function preservation
Primary composite endpoint met: 50% of TULSA patients preserved erectile function and continence at 6 months vs 24% for RP (p<0.05, risk ratio 2.1).
-
Director Kris Shah resigns; Frank Baylis appointed to board of Profound Medical
Kris Shah resigned from Profound Medical's board effective March 5, 2026; no disagreement cited.
-
Profound Medical to present first CAPTAIN trial outcomes at EAU 2026, host investor call March 13
First CAPTAIN trial outcomes (TULSA vs radical prostatectomy) presented at EAU 2026 on March 13 at 9:40 a.m. EDT.
-
Profound Medical Q4 revenue $6M (+43% YoY), net loss $8.2M; installed base 78 TULSA-PRO
Q4 revenue record $6.0M (+43% YoY); net loss $8.2M ($0.27/sh) vs $4.9M loss year ago.
-
INOVAIT honored Profound with the 2025-2026 Mount Logan Award for TULSA Procedure commercialization.
-
Profound Medical schedules Q4/FY2025 earnings release and call for March 5, 2026
Earnings results will be released after market close on Thursday, March 5, 2026.
-
Profound Medical announces PRO FAMILIA hospital completes 500th Sonalleve procedure
PRO FAMILIA Specialist Hospital in Rzeszów, Poland performed its 500th Sonalleve MRI-guided focused ultrasound procedure.
-
Profound Medical announces two February investor conferences
Lake Street Life-Sciences Invitational Feb 4-5 in Scottsdale, AZ; one-on-one meetings.
-
Mount Sinai treats first prostate cancer patient with Profound's TULSA-PRO system
Mount Sinai Hospital (ranked #6 for Urology) is first in Metro New York to offer TULSA-PRO incision-free, MRI-guided prostate treatment.
-
Profound Medical TULSA-PRO installed base reaches 78 systems, exceeding 2025 target of 75
TULSA-PRO installed base stood at 78 systems as of Dec. 31, 2025, above the goal of 75.
-
Johns Hopkins Hospital treated its first non-clinical-trial prostate cancer patient using Profound's TULSA-PRO system.
-
Profound Medical closes $6.45M private placement of 921,428 shares at $7.00 each
Issued 921,428 common shares at US$7.00 per share to Canadian investors for gross proceeds of ~US$6.45M.
-
Sold 5,142,870 common shares at $7.00 each in registered direct offering; gross proceeds ~$36M.
-
Launched TULSA-AI Volume Reduction module for BPH at RSNA; reduces procedure times and enables same-day stacking.
-
One-time cash payment of CDN$90,000 (US$64,000) and 5% royalty on Canadian net sales for 15 years.
-
Exclusive distribution and supply agreement for TULSA-PRO and Sonalleve in Saudi Arabia with Al Faisaliah Medical Systems Co.
-
Profound Medical signs exclusive distribution deal for TULSA-PRO in Australia, New Zealand
Exclusive distribution & supply agreement with Getz Healthcare for TULSA-PRO system in Australia and New Zealand.
-
Profound Medical reports preliminary Q3 revenue $5.2-5.3M, up 84-87% YoY
Preliminary unaudited Q3 2025 revenue of $5.2-5.3M vs $2.8M in Q3 2024, growth 84-87%.
-
Net loss of $15.7M ($0.52/share) vs $6.9M ($0.28/share) in Q2 2024; revenue unchanged at $2.2M.
-
Profound Medical names former NFL safety Leonard Wheeler as TULSA-PRO Global Ambassador
Leonard Wheeler, a former NFL player who underwent TULSA procedure for prostate cancer, joins Profound as Global Ambassador to promote TULSA-PRO.
-
Shareholders elect all six directors, approve auditor and share option plan
All six director nominees elected with 92.4%-97.0% votes for; Arun Menawat received 94.5%.
-
Profound Medical Q1 2025 revenue $2.6M (+82% YoY); net loss $10.7M vs $6.6M
Revenue $2.6M, up 82% from $1.4M in Q1 2024; gross margin 71% vs 60%.
-
CAPTAIN RCT peri-operative data: median blood loss 0 vs 100 mL and length of stay 0.29 vs 1.24 days for TULSA vs robotic prostatectomy (p<0.001).
-
CAPTAIN trial: TULSA shows zero blood loss, shorter stay vs robotic prostatectomy (p<0.001)
Median blood loss 0 mL (TULSA) vs 100 mL (RP); length of stay 0.29 vs 1.24 days (p<0.001).
-
Profound Medical releases proxy circular for May 14, 2025 annual meeting
Annual and special meeting scheduled for May 14, 2025; record date April 4, 2025.
-
Profound Medical restates Q1-Q3 2024 financials due to $472k revenue error; Q4 revenue up 108% YoY
Revenue overstated by $472k in Q1 2024; prior 6-K filings for Q1-Q3 2024 no longer reliable.
-
Profound Medical Q4 revenue up ~105-110% YoY; switches to US GAAP
Preliminary Q4 2024 revenue $4.1-4.2M, YoY growth 105-110%, sequential growth 45-48%.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.90 · Median 0.53 · Most common event other_material